Literature DB >> 20040911

Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues.

Florian Kühnel1, Engin Gürlevik, Thomas C Wirth, Nina Strüver, Nisar P Malek, Martina Müller-Schilling, Michael P Manns, Amancio Carnero, Lars Zender, Stefan Kubicka.   

Abstract

A hallmark of human tumors is the loss of p53 or its transcriptional functions. In this study, we describe the generation of the conditionally replicating adenovirus Adp53sensor for the treatment of p53-dysfunctional tumors. p53-selective attenuation of viral replication was achieved by using p53-dependent expression of the transcriptional repressor Gal4-KRAB that was directed against the adenoviral E1A locus. Adp53sensor shows efficient replication in p53-dysfunctional, but not in p53-active cells. In p53-dysfunctional cells, p53-analogous transcriptional activity by other p53 family members was not sufficient to compromise replication of Adp53sensor. In comparison with a genetically similar, but p53-insensitive virus, Adp53sensor replication was inhibited after systemic infection of p53-wt-mice, but not in p53-ko-mice thus confirming the correct function of the chosen approach. Adp53sensor showed efficient lytic and replicative properties in all investigated cells with p53-dysfunction and successfully inhibited the growth of subcutaneous xenotransplants in vivo. We further demonstrated that intravenous injection of Adp53sensor lead to significantly reduced liver damage compared to the control virus. Together, our data show that Adp53sensor is an oncolytic, p53-selective adenovirus for efficient treatment of p53-dysfunctional tumors with a favorable toxicity profile. Moreover, Adp53sensor provides a strategy that should be applicable to other transcriptionally regulated DNA viruses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20040911      PMCID: PMC2890106          DOI: 10.1038/mt.2009.298

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  44 in total

1.  p63 and p73 are required for p53-dependent apoptosis in response to DNA damage.

Authors:  Elsa R Flores; Kenneth Y Tsai; Denise Crowley; Shomit Sengupta; Annie Yang; Frank McKeon; Tyler Jacks
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

2.  E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection.

Authors:  Urs Hobom; Matthias Dobbelstein
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 3.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

4.  Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB.

Authors:  P Löser; G S Jennings; M Strauss; V Sandig
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.

Authors:  Florian Kühnel; Lars Zender; Thomas Wirth; Bernd Schulte; Christian Trautwein; Michael Manns; Stefan Kubicka
Journal:  Cancer Gene Ther       Date:  2004-01       Impact factor: 5.987

Review 6.  Control of apoptosis by p53.

Authors:  Jordan S Fridman; Scott W Lowe
Journal:  Oncogene       Date:  2003-12-08       Impact factor: 9.867

7.  Chemosensitivity linked to p73 function.

Authors:  Meredith S Irwin; Keiichi Kondo; Maria Carmen Marin; Lynn S Cheng; William C Hahn; William G Kaelin
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

8.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

9.  E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus.

Authors:  Michael A Thomas; Robin S Broughton; Felicia D Goodrum; David A Ornelles
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

10.  Hepatitis B virus X protein partially substitutes for E1A transcriptional function during adenovirus infection.

Authors:  J Schaack; H F Maguire; A Siddiqui
Journal:  Virology       Date:  1996-02-15       Impact factor: 3.616

View more
  4 in total

1.  Homologous recombination-based adenovirus vector system for tumor cell-specific gene delivery.

Authors:  Qin Lu; Xun Ye; Fang Liu; Yi Zhao; Jie Qin; Min Liang; Chao Fang; Hong-Zhuan Chen
Journal:  Cancer Biol Ther       Date:  2013-06-12       Impact factor: 4.742

2.  Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.

Authors:  Engin Gürlevik; Norman Woller; Nina Strüver; Peter Schache; Arnold Kloos; Michael P Manns; Lars Zender; Florian Kühnel; Stefan Kubicka
Journal:  Mol Ther       Date:  2010-08-10       Impact factor: 11.454

Review 3.  Oncolytic viruses: adenoviruses.

Authors:  Julia Niemann; Florian Kühnel
Journal:  Virus Genes       Date:  2017-07-12       Impact factor: 2.198

4.  Meganuclease-mediated virus self-cleavage facilitates tumor-specific virus replication.

Authors:  Engin Gürlevik; Peter Schache; Anneliese Goez; Arnold Kloos; Norman Woller; Nina Armbrecht; Michael P Manns; Stefan Kubicka; Florian Kühnel
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.